Abstract: The invention relates to the use of compounds of the general formula (I) ##STR1## wherein R.sup.1 represents a hydrogen atom or a C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl-(C.sub.1-4) alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, phenyl or phenyl-C.sub.1-3 alkyl group; and one of the groups represented byR.sup.2, R.sup.3 and R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6 alkenyl or phenyl-C.sub.1-3 alkyl group and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkyl group; and physiologically acceptable salts and solvates thereof, for the relief of nausea and vomiting and/or the promotion of gastric emptying and for the manufacture of a medicament for this purpose. Promotion of gastric emptying may be for the relief of gastro-intestinal disorders associated with gastric stasis or may be of advantage in radiological examination procedures.
Type:
Grant
Filed:
December 9, 1991
Date of Patent:
August 31, 1993
Assignee:
Glaxo Group Limited
Inventors:
Michael B. Tyers, Ian H. Coates, David C. Humber, George B. Ewan, James A. Bell
Abstract: Oral compositions containing a gastroprotective amount of zirconium aluminum glycinate, aluminum chlorohydrate or a mixture thereof are disclosed. A method for protecting the gastric mucosa against injury caused by a gastric irritant such as NSAIDs is also disclosed.
Abstract: The invention provides methods for preventing neural tissue damage caused by injury to the central nervous system (CNS) by the administration of a therapeutically effective amount of an adenosinergic agent. One aspect of the invention is directed toward continuous administration of a therapeutically effective amount of an adenosinergic agent for a period of time sufficient to prevent neural tissue damage. In another aspect of the present invention, the adenosinergic agents may be administered on several occasions during the prolonged period of treatment, so long as the doses of adenosinergic agents are spaced in time so that a therapeutically effective concentration of adenosinergic agent is maintained for a period of time sufficient to prevent neural tissue damage.
Abstract: Disclosed is a method for reducing NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal a nitric-oxide generating compound, or a physiologically acceptable salt thereof, in a concentration effective to cause such reduction. Also disclosed is a method for reducing NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal nitroprusside, nitroglycerin, or a derivative of one of those compounds, in a concentration effective to cause such reduction.
Type:
Grant
Filed:
September 22, 1992
Date of Patent:
August 10, 1993
Assignee:
The Children's Medical Center Corporation
Abstract: A method of treating or preventing motion sickness is disclosed which comprises administering an anti-motion sickness effective amount of an anticonvulsant compound such as phenytoin, ethotoin, primidone, ethosuximide or carbamazepine, in combination with a potentiating amount of an antitussive or cough suppressant agent such as dextromethorphan, levopropoxyphene, muscaphene, pholocodeine, or carbetapentene. The antitussive compounds of the present invention act as potentiating agents so as to enable effective treatment or prevention of motion sickness using a reduced amount of the anticonvulsant compound normally used in such treatment. The method of the present invention reduces the potential for various side effects and thus provides a safer and more effective method of treatment for motion sickness than prior art methods.
Abstract: Methods for the treatment of secretory diarrhea comprised of administering to a patient in need thereof, an effective amount of a CFTR chloride channel blocker or a potassium channel opener are disclosed. The CFTR chloride channel blocker is a sulfonylurea of the group consisting of tolbutamide, glibenclamide, and related analogs. The potassium channel opener is selected from the group consisting of diazoxide, lemakalim, and minoxidil sulfate.
Abstract: A stable solid pharmaceutical composition for oral administration comprising dapiprazole or a physiologically acceptable acid salt thereof together with a pharmaceutically acceptable inert excipient and magnesium oxide as a degradation retarding agent is disclosed.
Type:
Grant
Filed:
July 20, 1992
Date of Patent:
August 10, 1993
Assignee:
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
Abstract: A method for activating potassium channels and for treating hypertension, addiction, asthma, incontinence, and other conditions treatable by potassium channel activators, such as spasms and convulsions, comprising administering a compound having the formula: ##STR1## wherein R is a saturated or unsaturated group having from 1 to 4 carbon atoms which is optionally substituted by lower alkyl, lower alkenyl or lower alkoxy groups; andwherein R' is hydrogen, lower alkyl, lower alkenyl, or aralkyl.
Abstract: Dipeptidic amides having the formula, RCO--NHCH.sub.2 CONH--CH(CH.sub.2 0H)--COOH wherein R is a linear or branched alkyl group, optionally unsaturated and containing 7 to 17 carbon atoms, are used in cosmetic or pharmaceutical compositions for the treatment or care of the skin.
Abstract: A method of treatment is provided for reducing or eliminating psychomotor addiction in mammalian subjects, employing as an active agent 3-phenoxypyridine or a pharmaceutically acceptable acid-addition salt thereof.
Abstract: The invention relates to a method of treating psychosis in a mammal which comprises administering to the mammal an effective amount of a dopamine receptor antagonist antipsychotic and a sigma receptor antagonist having greater affinity for sigma receptors than for dopamine receptors, in an amount effective to selectively enhance the antipsychotic effects of the dopamine receptor antagonist relative to the adverse side effects of the dopamine receptor antagonist.
Abstract: Analogs of 6-mercaptopurine have been found to enhance the detoxification of various electrophilic toxicants in vivo, while having minimal cytotoxicity themselves. This property allows such compounds to act as scavengers for electrophilic toxicants, thereby preventing the cellular damage caused by such toxic agents.
Type:
Grant
Filed:
March 4, 1992
Date of Patent:
July 27, 1993
Assignee:
The Board of Regents, The University of Texas System
Abstract: The invention relates to a method for the treatment of atherosclerosis, thrombosis and/or of peripheral vessel disease by administration of angiotensin converting enzyme inhibitors. Administration of compounds of the formula I ##STR1## in which n is 1 or 2, R, R.sup.1, R.sup.2 and R.sup.3 are identical or different and each denotes hydrogen or an organic radical, and R.sup.4 and R.sup.5 form, together with the atoms carrying them, a mono-, bi- or tricyclic heterocyclic ring system, is preferred. The invention also relates to angiotensin converting enzyme inhibitors and to agents containing them for administration for the treatment of the abovementioned diseases.
Abstract: The invention concerns the use of i.a. 1-[2-(2-naphthyl)-ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyr idine and its pharmaceutically acceptable addition salts for the preparation of medicaments suitable for the treatment and/or prophylaxis of neuronal degenerative processes including senile dementia, vascular dementia, and Alzheimer's disease.
Abstract: Compounds of the formula I ##STR1## in which R.sub.1 is lower alk-2-en-1-yl, lower alk-3-en-2-yl, lower alk-2-yn-1-yl or lower alkyl substituted in the 2,3-position by radicals which can be eliminated to give a double bond, R.sub.2 is hydrogen and R.sub.3 is methyl which is unsubstituted or substituted by radicals which can be eliminated together with hydrogen R.sub.2 to give a double bond or R.sub.2 and R.sub.3 are both hydrogen or lower alkyl or are together methylene and R.sub.4 is a group of the formula Ia, Ib or Ic ##STR2## in which R.sub.5 is hydrogen, lower alkyl, lower alk-2-en-1-yl or lower alk-2-yn-1-yl and R.sub.6 is a group of the formula Id or Ie ##STR3## in which R.sub.1, R.sub.2, R.sub.3 and R.sub.5 are as defined, and their pharmaceutically acceptable salts can be used in a novel manner for the treatment of diseases of the rheumatoid type.
Type:
Grant
Filed:
April 10, 1992
Date of Patent:
July 20, 1993
Assignee:
Ciba-Geigy Corporation
Inventors:
Ulrich Feige, Irmgard Wiesenberg, Leo Widler, Pier G. Ferrini, Martin Missbach
Abstract: The invention relates to the use of compounds of formula (I) ##STR1## wherein Im represents an imidazolyl group of formula: ##STR2## and R.sup.1 represents a hydrogen atom or a group selected from C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, phenylC.sub.1-3 alkyl, phenylmethoxymethyl, phenoxyethyl, phenoxymethyl, --CO.sub.2 R.sup.5, --COR.sup.5, --CONR.sup.5 R.sup.6 or --SO.sub.2 R.sup.5 (wherein R.sup.5 and R.sup.6, which may be the same or different, each represents a hydrogen atom, a C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl group, or a phenyl or phenylC.sub.1-4 alkyl group, in which the phenyl group is optionally substituted by one or more C.sub.1-4 alkyl, C.sub.1-4 alkoxy or hydroxy groups or halogen atoms, with the proviso that R.sup.5 does not represent a hydrogen atom when R.sup.1 represents a group --CO.sub.2 R.sup.5 or --SO.sub.2 R.sup.5);one of the groups represented by R.sup.2, R.sup.3 and R.sup.
Type:
Grant
Filed:
July 10, 1992
Date of Patent:
July 20, 1993
Assignee:
Glaxo Group Limited
Inventors:
Ian H. Coates, Alexander W. Oxford, Peter C. North, Michael B. Tyers
Abstract: The invention relates to compositions comprising combinations of a PAF antagonist and a LTD.sub.4 antagonist which combinations synergistically provide protection against allergic reactions such as antigen-induced death in mammals.In another aspect, the invention relates to the use of the referred to combinations in the treatment of allergic reactions.